The Impact of COVID-19 in Gastroenterology and Hepatology.
J Clin Gastroenterol
; 55(9): 757-765, 2021 10 01.
Article
in English
| MEDLINE | ID: covidwho-1367075
ABSTRACT
The 2019 coronavirus disease (COVID-19), an airborne infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global pandemic. SARS-CoV-2 relies on the angiotensin-converting enzyme 2 receptor for cellular entry and the abundance of this receptor in the gastrointestinal (GI) tract may help explain the GI manifestations, including dysgeusia, nausea, vomiting, diarrhea, and abdominal pain, present in over 40% of infected patients. GI tract involvement also raises the concern for oral-fecal transmission which is poorly understood. Outcome studies in COVID-19 patients with preexisting liver disease and inflammatory bowel disease show predominantly mild transaminase elevations and no increased risk from the use of biological agents in inflammatory bowel disease patients. High-dose corticosteroids, however, should be avoided. As endoscopic procedures are aerosol-generating, modifications to clinical practice is necessary to minimize the spread of COVID-19. We have reviewed current literature to describe the impact of COVID-19 in gastroenterology and hepatology as well as targets of future research.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Gastroenterology
/
Gastrointestinal Diseases
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
J Clin Gastroenterol
Year:
2021
Document Type:
Article
Affiliation country:
Mcg.0000000000001600
Similar
MEDLINE
...
LILACS
LIS